Double-blind Trial of Mannitol Cream to Block the Effect of Capsaicin Cream

NCT ID: NCT01963910

Last Updated: 2014-03-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-12-31

Study Completion Date

2014-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Capsaicin is a TRPV1 (transient receptor potential vanilloid 1) agonist, causing pain upon application. The investigators wish to determine whether mannitol blocks the effect of capsaicin application. As both cream bases are identical and mannitol addition is the only difference between the creams, if the mannitol cream is more effective in blocking the effect of capsaicin on the TRPV1 (transient receptor potential vanilloid 1) receptor, the investigators will have established that mannitol down-regulates or blocks the TRPV1 (transient receptor potential vanilloid 1) receptor.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Capsaicin cream, which stimulates the TRPV1 (transient receptor potential vanilloid 1) receptor, causing a burning sensation, will be applied to both halves of the upper lip until a burning sensation with 8/10 intensity on an NRS (Visual Analog Scale) scale is experienced or five minutes have elapsed. Following this, the capsaicin cream will be wiped off and 30% mannitol in vehicle cream ( isopropyl palmitate, caprylic capric triglyceride, propylene glycol, ceteareth 20, cetearyl alcohol, glyceryl stearate, polyethylene glycol 100 stearate, dimethicone, octyldodecanol, lecithin, ethylhexyl glycerin and phenoxy ethanol) will be applied to one half of the upper lip, and vehicle cream alone will be applied to the other half. Cream assignment will be randomized and neither the subject nor the person applying the cream will know which half upper lip has which cream. Every minute for 10 minutes, the heat sensation felt in each half upper lip will be measured, using a visual scale from 0 to 10. A repeated measures analysis of variance will compare the NRS (Visual Analog Scale) scores from the 30% mannitol cream, to the NRS (Visual Analog Scale)scores from the vehicle cream. Significance will be accepted if P less than .05.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mannitol in vehicle cream

Once the capsaicin has been removed, .2 mL of 30% mannitol in vehicle cream will be applied to one half of the upper lip and kept there for 10 minutes.

Group Type ACTIVE_COMPARATOR

30% Mannitol in vehicle cream

Intervention Type DRUG

applied to one half of the upper lip following removal of capsaicin cream.

Vehicle Cream

Once the capsaicin has been removed, .2 mL of vehicle cream will be applied to the other half of the upper lip and kept there for 10 minutes.

Group Type PLACEBO_COMPARATOR

vehicle cream

Intervention Type DRUG

application to the other half of the upper lip following capsaicin cream removal

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

30% Mannitol in vehicle cream

applied to one half of the upper lip following removal of capsaicin cream.

Intervention Type DRUG

vehicle cream

application to the other half of the upper lip following capsaicin cream removal

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

mannitol cream Mannitol mannite manna sugar C6H8(OH)6

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age between 19 and 80 years

Exclusion Criteria

* Diet containing capsaicin (Cayenne pepper, capsicum) (spicy foods), more than once a week.
* Meal containing capsaicin (spicy foods) within 5 days prior to the experiment.
* Any lesion, cracking, cold sore or abrasion on the lips
* Inability to tolerate capsaicin containing "spicy foods"
* Wearing lipstick or lip balm on the upper lip
* Inability to fill out an NRS pain scale
* Use of painkilling medication, within 24 hours of the study.
* Allergy to any of the ingredients of the creams, or to mannitol
* History of contact or allergic dermatitis
* Pregnant or nursing women
Minimum Eligible Age

19 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of British Columbia

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Helene Bertrand

Clinical instructor Department of Family Practice

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Helene Bertrand, MD, CM, CCFP

Role: PRINCIPAL_INVESTIGATOR

Department of family practice, University of British Columbia

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Dr. Helene Bertrand Inc., 220-1940 Lonsdale Ave.

North Vancouver, British Columbia, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

References

Explore related publications, articles, or registry entries linked to this study.

Ngom PI, Dubray C, Woda A, Dallel R. A human oral capsaicin pain model to assess topical anesthetic-analgesic drugs. Neurosci Lett. 2001 Dec 28;316(3):149-52. doi: 10.1016/s0304-3940(01)02401-6.

Reference Type BACKGROUND
PMID: 11744224 (View on PubMed)

Boudreau SA, Wang K, Svensson P, Sessle BJ, Arendt-Nielsen L. Vascular and psychophysical effects of topical capsaicin application to orofacial tissues. J Orofac Pain. 2009 Summer;23(3):253-64.

Reference Type BACKGROUND
PMID: 19639105 (View on PubMed)

Bertrand H, Kyriazis M, Reeves KD, Lyftogt J, Rabago D. Topical Mannitol Reduces Capsaicin-Induced Pain: Results of a Pilot-Level, Double-Blind, Randomized Controlled Trial. PM R. 2015 Nov;7(11):1111-1117. doi: 10.1016/j.pmrj.2015.05.002. Epub 2015 May 12.

Reference Type DERIVED
PMID: 25978942 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

H13-01551

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Transient Receptor Potential Channels
NCT06444594 RECRUITING EARLY_PHASE1
Menthol In Neuropathy Trial
NCT04276727 COMPLETED PHASE2
The Role of TRP Channels in DPN
NCT07237022 RECRUITING